[(1R,2R)-2-(methylsulfonyloxymethyl)cyclohexyl]methyl methanesulfonate

We are [(1R,2R)-2-(methylsulfonyloxymethyl)cyclohexyl]methyl methanesulfonate CAS:186204-35-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:[(1R,2R)-2-(methylsulfonyloxymethyl)cyclohexyl]methyl methanesulfonate
CAS.NO:186204-35-3
Synonyms:(R)-trans-1,2-Bis-methansulfonyloxymethyl-cyclohexan
(R,R)-1,2-Bis(Methanesulphonyloxymethyl)cyclohexane
(1R,2R)-(-)-trans-cyclohexane-1,2-diylbis(methylene)dimethanesulfonate
Molecular Formula:C10H20O6S2
Molecular Weight:300.39200
 
Physical and Chemical Properties:
Density:1.27
Boiling point:495.284ºC
Flash point:253.339ºC
 
Specification:
Appearance:Off-white solid
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediates of Lurasidone
 
Note:The product under valid patents will not be offered to the countries covered by patents.

[(1R,2R)-2-(methylsulfonyloxymethyl)cyclohexyl]methyl methanesulfonate


Related News: However, pharmaceutical intermediates are subdivided into primary intermediates and advanced intermediates. Because primary intermediate suppliers can only provide simple intermediate production, they are at the front end of the industrial chain. The pressure of competition and price is the greatest. The price fluctuations of basic chemical raw materials have a greater impact on them.Methyl 1H-1,2,4-triazole-3-carboxylate The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.8-chloro-1-octanol acetate CAS:21727-90-2 Active pharmaceutical ingredients directly impact disease.N,N'-Bis(benzyloxycarbonyl)-1H-pyrazole-1-carboxamidine As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.

Related Products
Product Name
2-Bromo-4′-methylacetophenone View Details
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone View Details
1,3-Bis(2,4-Diaminophenoxy)Propane 4HCl View Details
Diethyl 2,3-dichlorobutanedioate manufacturer 6-Chloroimidazo[1,2-b]pyridazine manufacturer 4-Methyl-2-pentanone manufacturer 1,3-Dinitro-2-chloro-5-trifluoromethylbenzene manufacturer 2,6-Dimethylfluorobenzene manufacturer